SCHEMBL1874237

SCHEMBL1874237

CC(C)C(=O)NC1CCc2c(c3cc(C#N)ccc3n2Cc2ccccc2C(F)(F)F)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 7/20 0.43
C5AR1 P21730 1/20 0.40
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.39
TNKS O95271 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38
XIAP P98170 1/20 0.37
PRKCQ Q04759 3/20 0.37
PRKCD Q05655 3/20 0.37
RORC P51449 2/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
TBXA2R P21731 1/20 0.36
PTGDR Q13258 1/20 0.36
PGR P06401 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
P2RX7 Q99572 1/20 0.36
SSTR4 P31391 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887084 0.89 PTGDR2 (0.43) PTGDR2XIAPRORCMTNR1AMTNR1B
SCHEMBL1876521 0.89 PTGDR2 (0.43) PTGDR2XIAPRORCMTNR1AMTNR1B
SCHEMBL1875284 0.88 PTGDR2 (0.42) PTGDR2XIAPRORCMTNR1AMTNR1B
SCHEMBL1879708 0.88 PTGDR2 (0.42) PTGDR2XIAPRORCMTNR1AMTNR1B
SCHEMBL14625188 0.88 PTGDR2 (0.44) PTGDR2FABP3FABP4MTNR1AMTNR1B
SCHEMBL1875281 0.88 PTGDR2 (0.42) PTGDR2XIAPRORCMTNR1AMTNR1B
SCHEMBL12636982 0.87 PTGDR2 (0.41) PTGDR2XIAPRORCMTNR1AMTNR1B
SCHEMBL1879437 0.87 MTNR1A (0.49) PTGDR2FABP4XIAPRORCMTNR1A
SCHEMBL1881732 0.86 PTGDR2 (0.43) PTGDR2XIAPRORCMTNR1AMTNR1B
SCHEMBL1882871 0.86 PTGDR2 (0.41) PTGDR2XIAPRORCMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
EP-1902026-B1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) LILLY CO ELI (US) 2010-02-17 EP disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
EP-1902026-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2008-03-26 EP disclosed
WO-2007002181-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS AR, SHBG, CYP17A1 PTGDR2 437/4885C5AR1 2139/4885FABP3 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.